-
Posted by
Two Blokes Mon at 3:45 AM -
Filed in
Stock
-
2 views
FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional returns compared to the broader Health Care sector, despite its high 0.56% expense ratio. A closer look at performance reveals that FBT is subject to periods of significant gains and losses, though it has struggled over the last five and ten-year periods.
